Study of galvokimig for non-cystic fibrosis bronchiectasis
Part of Lungs & breathing clinical trials.
This study tests a new medicine called galvokimig for adults with non-cystic fibrosis bronchiectasis, a condition where airways are damaged and cause chronic cough and sputum. The goal is to see if it reduces flare-ups and improves lung health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with bronchiectasis (confirmed by a special CT scan) that is not due to cystic fibrosis.
- You currently produce sputum (phlegm) and have a history of chronic cough or mucus.
- You have had at least 2 moderate or severe flare-ups in the last year, or 1 severe flare-up in the last 6 months.
- Your lung function is at least 30% of what is predicted for your age and height.
- You are willing to use contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled medication called CSL787 to see if it can help people with non-cystic fibrosis bronchiectasis (a lung condition that causes frequent infections and breathing problems). The study looks at different doses and checks how well the drug works and if it is safe.
This trial tests a new medicine, HSK31858, for people with non-cystic fibrosis bronchiectasis (a lung condition causing chronic cough and infections). It aims to see if the drug reduces lung flare-ups and improves symptoms.
This study tests an inhaled medicine (GDC-6988) to see if it is safe and helps clear mucus from the lungs in people with mucus-related lung diseases like chronic bronchitis, COPD, or bronchiectasis. You may qualify if your lung function is fairly stable and you produce daily mucus.
This study tests how safe an experimental inhaled medicine (HSK31858) is for people with non-cystic fibrosis bronchiectasis, a lung condition where airways are damaged and collect mucus. You can only join if you already completed a previous HSK31858 study.
This study tests an experimental drug called Galvokimig (taken as a pill) to see if it can reduce COPD flare-ups and improve lung function in people with moderate to severe COPD and chronic bronchitis. It is for those who have had recent flare-ups and are already using maintenance inhalers.
This trial tests if a new drug, GSK3862995B, is safe and effective for adults with bronchiectasis. It might help reduce lung infections and improve symptoms.
Hear when a new Non-cystic Fibrosis Bronchiectasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.